— Companies to jointly validate novel drug targets —- Scipher eligible for upfront, opt-in and milestone payments —- Galapagos to progress selected targets into drug discovery — Mechelen, Belgium and Boston, USA; 12 August 2020 –...
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine, a precision immunology company that helps match patients with their most effective therapy, today announced successful results...
Appoints Slava Akmaev, Ph.D., as Chief Technology Officer WALTHAM, Mass.–(BUSINESS WIRE)–Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed most effective therapy, today announces the addition of Slava...
Investment to Accelerate Molecular Diagnostic Product Selection, Development and Accessibility WALTHAM (February 19, 2020) — Scipher Medicine, a developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy, announced...
Technology to significantly improve outcomes for autoimmune disease patients by ensuring optimal therapy is prescribed from day one WALTHAM, MA – December 19, 2019—Scipher Medicine, developer of a molecular technology platform used to ensure patients are prescribed...
Scipher aims to improve drug response predictions by incorporating protein interaction networks in its gene expression analysis algorithms. To improve the accuracy of therapeutic response predictions, Scipher has incorporated protein-protein interaction map into its...
